Aurobindo Pharma surged 14.56% to Rs 573.05 after the company's Hyderabad-based formulations manufacturing facility received an EIR from the US drug regulator.
The drug maker said that with regard to the USFDA inspection of unit IV, a general injectable formulation manufacturing facility of the company, the company has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from USFDA.
Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics.
Powered by Capital Market - Live News